| Antiviral | EC50 ratio | Phenotype | Strain | Source | Marker | Assay | Reference |
|---|---|---|---|---|---|---|---|
| Ganciclovir | 4.00 | Intermediate level resistance | Recombinant | Details | Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024) | ||
| Cidofovir | 11.00 | High level resistance | Recombinant | Details | Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024) | ||
| Foscarnet | 1.20 | No resistance | Recombinant | Details | Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024) |
| Mutant | Resistances |
|---|---|
| L545S |
Ganciclovir:
|
| L545S |
Cidofovir:
|
| L545S |
Foscarnet:
|
| L545W |
Ganciclovir:
|
| L545W |
Cidofovir:
|
| L545W |
Foscarnet:
|